Advanced Magnetics Combidex
Executive Summary
NDA for the magnetic resonance imaging contrast agent may be taken to FDA's Medical Imaging Advisory Committee in May, firm says. The company expects an action letter by June 19, based on priority review status granted on the Dec. 21 submission